232
M. Mével et al. / Journal of Controlled Release 143 (2010) 222–232
[20] C.R. Safinya, Structures of lipid-DNA complexes: supramolecular assembly and
gene delivery, Curr. Opin. Struct. Biol. 11 (2001) 440–448.
[44] M. Oliver, M.R. Jorgensen, A. Miller, The facile solid-phase synthesis of cholesterol-
based polyamine lipids, Tet. Lett. 45 (2004) 3105–3107.
[21] R. Koynova, L. Wang, R.C. MacDonald, An intracellular lamellar-nonlamellar phase
transition rationalizes the superior performance of some cationic lipid transfec-
tion agents, Proc. Natl Acad. Sci. USA 103 (2006) 14373–14378.
[22] A. Noguchi, T. Furuno, C. Kawaura, M. Nakanishi, Membrane fusion plays an
important role in gene transfection mediated by cationic liposomes, FEBS Lett. 422
(1998) 169–173.
[23] H. Farhood, N. Serbina, L. Huang, The role of dioleoyl phosphatidylethanolamine in
cationic liposome mediated gene transfer, Biochim. Biophys. Acta 1235 (1995)
289–295.
[45] N. Sakai, S. Matile, Anion-mediated transfer of polyarginine across liquid and
bilayer membranes, J. Am. Chem. Soc. 125 (2003) 14348–14356.
[46] N. Sakai, T. Takeuchi, S. Futaki, S. Matile, Direct observation of anion-mediated
translocation of fluorescent oligoarginine carriers into and across bulk liquid and
anionic bilayer membranes, Chem. Biochem. 6 (2005) 114–122.
[47] C. Dardonville, R. Brun, Bisguanidine, bis(2-aminoimidazoline), and polyamine
derivatives as potent and selective chemotherapeutic agents against Trypanosoma
brucei rhodesiense, synthesis and in vitro evaluation, J. Med. Chem. 47 (2004)
2296–2307.
[24] A.L. Bailey, P.R. Cullis, Membrane fusion with cationic liposomes: effects of target
membrane lipid composition, Biochemistry 36 (1997) 1628–1634.
[25] S. Li, M.A. Rizzo, S. Bhattacharya, L. Huang, Characterization of cationic lipid-
protamine-DNA (LPD) complexes for intravenous gene delivery, Gene Ther. 5
(1998) 930–937.
[48] C.L. Densmore, T.H. Giddings, J.C. Waldrep, B.M. Kinsey, V. Knight, Gene transfer by
guanidinium-cholesterol: dioleoylphosphatidyl-ethanolamine liposome-DNA
complexes in aerosol, J. Gene Med. 1 (1999) 251–264.
[49] D. Luton, N. Oudrhiri, P. de Lagausie, A. Aissaoui, M. Hauchecorne, et al., Gene
transfection into fetal sheep airways in utero using guanidinium-cholesterol
cationic lipids, J. Gene Med. 6 (2004) 328–336.
[26] O. Boussif, J. Gaucheron, C. Boulanger, C. Santaella, H.V.J. Kolbe, et al., Enhanced in
vitro and in vivo cationic lipid-mediated gene delivery with
a
fluorinated
[50] B.E. Yingyongnarongkul, M. Howarth, T. Elliott, M. Bradley, Solid-phase synthesis
of 89 polyamine-based cationic lipids for DNA delivery to mammalian cells, Chem.
Eur. J. 10 (2004) 463–473.
[51] J. Sen, A. Chaudhuri, Design, syntheses, and transfection biology of novel non-
cholesterol-based guanidinylated cationic lipids, J. Med. Chem. 48 (2005)
812–820.
[52] M.S. Bernatowicz, Y. Wu, G.S. Matsueda, H-Pyrazole-1-carboxamidine hydrochlo-
ride an attractive reagent for guanylation of amines and its application to peptide
synthesis, J. Org. Chem. 57 (1992) 2497–2502.
[53] N. Kamaly, T. Kalber, A. Ahmad, M.H. Oliver, P.W. So, A.H. Herlihy, J.D. Bell, M.R.
Jorgensen, A.D. Miller, Bimodal paramagnetic and fluorescent liposomes for cellular
and tumor magnetic resonance imaging, Bioconjug. Chem. 19 (2008) 118–129.
[54] E. Uchida, H. Mizuguchi, A. Ishii-Watabe, T. Hayakawa, Comparison of the
efficiency and safety of non-viral vector-mediated gene transfer into a wide range
of human cells, Biol. Pharm. Bull. 25 (2002) 891–897.
glycerophosphoethanolamine helper lipid, J. Gene Med. 3 (2001) 109–114.
[27] J. Gaucheron, C. Boulanger, C. Santaella, N. Sbirrazzuoli, O. Boussif, et al., In vitro
cationic lipid-mediated gene delivery with fluorinated glycerophosphoethanola-
mine helper lipids, Bioconjug. Chem. 12 (2001) 949–963.
[28] S. Fletcher, A. Ahmad, E. Perouzel, M.R. Jorgensen, A.D. Miller, A dialkynoyl
analogue of DOPE improves gene transfer of lower-charged, cationic lipoplexes,
Org. Biomol. Chem. 4 (2006) 196–199.
[29] S. Fletcher, A. Ahmad, W.S. Price, M.R. Jorgensen, A.D. Miller, Biophysical
properties of CDAN/DOPE-Analogue lipoplexes account for enhanced gene
delivery, Chem. BioChem. 9 (2008) 455–463.
[30] M. Mével, G. Breuzard, J.J. Yaouanc, J.C. Clement, P. Lehn, et al., Synthesis and
transfection activity of new cationic phosphoramidate lipids: high efficiency of an
imidazolium derivative, Chem. Biochem. 9 (2008) 1462–1471.
[31] M. Mével, C. Neveu, C. Goncalves, J.J. Yaouanc, C. Pichon, P.A. Jaffrès, P. Midoux,
Novel neutral imidazole-lipophosphoramides for transfection assays, Chem.
Commun. 21 (2008) 3124–3126.
[32] L. Stewart, M. Manvell, E. Hillery, C.J. Etheridge, R.G. Cooper, et al., Physico-
chemical analysis of cationic liposome–DNA complexes (lipoplexes) with respect
to in vitro and in vivo gene delivery efficiency, J. Chem. Soc., Perkin Trans. 2 (2001)
624–632.
[55] O. Argyros, S.P. Wong, M. Niceta, S.N. Waddington, S.J. Howe, et al., Persistent
episomal transgene expression in liver following delivery of a scaffold/matrix
attachment region containing non-viral vector, Gene Ther. 15 (2008) 1593–1605.
[56] Y. Naito, T. Yamada, K. Ui-Tei, S. Morishita, K. Saigo, siDirect: highly effective,
target-specific siRNA design software for mammalian RNA interference, Nucleic
Acids Res. 32 (2004) W124–W129.
[33] J.P. Behr, B. Demeneix, J.P. Loeffler, J. Perez-Mutul, Efficient gene transfer into
mammalian primary endocrine cells, Proc. Natl Acad. Sci. USA 86 (1989)
6982–6986.
[57] K. Ui-Tei, Y. Naito, F. Takahashi, T. Haraguchi, H. Ohki-Hamazaki, et al., Guidelines
for the selection of highly effective siRNA sequences for mammalian and chick
RNA interference, Nucleic Acids Res. 32 (2004) 936–948.
[34] P. Hawley-Nelson, V. Ciccarone, J. Gebeyehu, J. Jessee, P.L. Felgner, Lipofectamine
reagent : a new, higher efficiency polycationic liposome transfection reagent,
Focus 15 (1993) 73–79.
[58] P.L. Marion, F.H. Salazar, K. Liittschwager, B.B. Bordier, C. Seegers, M.A. Winters,
M. A. Frontiers in Viral Hepatitis, in: R. Schinazi, R.F. Sommadossi, J.P. Rice, (Eds.),
Elsevier Science, Amsterdam, pp. 197–202.
[35] F. Lamarche, M. Mével, T. Montier, L. Burel-Deschamps, P. Giamarchi, et al.,
Lipophosphoramidates as lipidic part of lipospermines for gene delivery,
Bioconjug. Chem. 18 (2007) 1575–1582.
[59] D.V. Morrissey, K. Blanchard, L. Shaw, K. Jensen, J.A. Lockridge, et al., Activity of
stabilized short interfering RNA in a mouse model of hepatitis B virus replication,
Hepatology 41 (2005) 1349–1356.
[36] A. Alshamsan, A. Haddadi, V. Incani, J. Samuel, A. Lavasanifar, et al., Formulation
and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine,
Mol. Pharmaceutics 6 (2009) 121–133.
[37] Y.T. Ko, A. Kale, A.W.C. Hartner, B. Papahadjopoulos-Sternberg, V.P. Torchilin, Self-
assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine
conjugates for systemic gene delivery, J. Control. Release 133 (2009) 132–138.
[38] M. Abbasi, H. Uludag, V. Incani, C.Y.M. Hsu, A. Jeffery, Further investigation of lipid-
substituted poly(L-lysine) polymers for transfection of human skin fibroblasts,
Biomacromolecules 9 (2008) 1618–1630.
[39] M. Keller, M.R. Jorgensen, E. Perouzel, A.D. Miller, Thermodynamic aspects and
biological profile of CDAN/DOPE and DC-Cho1/DOPE lipoplexes, Biochemistry 42
(2003) 6067–6077.
[40] S. Spagnou, A.D. Miller, M. Keller, Lipidic carriers of siRNA: differences in the
formulation, cellular uptake, and delivery with plasmid DNA, Biochemistry 43
(2004) 13348–13356.
[41] R.G. Cooper, C.J. Etheridge, L. Stewart, J. Marshall, S. Rudginsky, et al., Polyamine
analogues of 3β-[N-(N′, N′-dimethylaminoethane)carbamoyl]cholesterol (DC-Chol)
as agents for gene delivery, Chem. Eur. J. 4 (1998) 137–151.
[42] S. Carmona, M.R. Jorgensen, S. Kolli, C. Crowther, F.H. Salazar, P.L. Marion, M.
Fujino, Y. Natori, M. Thanou, P. Arbuthnot, A.D. Miller, Controlling HBV replication
in vivo by intravenous administration of triggered PEGylated siRNA nanoparticles,
Mol. Pharmaceutics 6 (2009) 706–717.
[43] T. Tagawa, M. Manvell, N. Brown, M. Keller, E. Perouzel, et al., Characterisation of
LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus
core peptide μ (mu) and plasmid DNA, Gene Ther. 9 (2002) 564–576.
[60] A.P. McCaffrey, H. Nakai, K. Pandey, Z. Huang, F.H. Salazar, et al., Inhibition of
hepatitis B virus in mice by RNA interference, Nat. Biotechnol. 21 (2003) 639–644.
[61] J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, et al., Therapeutic
silencing of an endogenous gene by systemic administration of modified siRNAs,
Nature (2004) 173–178.
[62] S.I. Kim, D. Shin, T.H. Choi, J.C. Lee, G.J. Cheon, et al., Systemic and specific delivery
of small interfering RNAs to the liver mediated by apolipoprotein A-I, Mol. Ther. 15
(2007) 1145–1152.
[63] K. Nishina, T. Unno, Y. Uno, T. Kubodera, T. Kanouchi, et al., Efficient in vivo
delivery of siRNA to the liver by conjugation of α-tocopherol, Mol. Ther. 16 (2008)
734–740.
[64] Y. Sato, K. Murase, J. Kato, M. Kobune, T. Sato, et al., Resolution of liver cirrhosis
using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific
chaperone, Nat. Biotechnol. 26 (2008) 431–442.
[65] D.V. Morrissey, J.A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, et al., Potent and
persistent in vivo anti-HBV activity of chemically modified siRNAs, Nat. Biotechnol.
23 (2005) 1002–1007.
[66] T.S. Zimmermann, A.C.H. Lee, A. Akinc, B. Bramlage, D. Bumcrot, et al., RNAi-
mediated gene silencing in non-human primates, Nature 441 (2006) 111–114.
[67] W. Li, F.C. Szoka, Lipid-based nanoparticles for nucleic acid delivery, Pharm. Res.
24 (2007) 438–449.
[68] Y. Chen, G. Cheng, R.I. Mahato, RNAi for treating hepatitis B viral infection, Pharm.
Res. 25 (2008) 72–86.